Valneva’s Ixchiq shows 95% 4-year antibody persistence, shares up 10%
PositiveFinancial Markets

Valneva has announced that its vaccine candidate Ixchiq demonstrates an impressive 95% persistence of antibodies over four years, leading to a 10% increase in its shares. This is significant as it suggests long-term effectiveness of the vaccine, which could enhance public confidence and drive demand. The positive market reaction reflects investor optimism about the potential for Ixchiq to play a crucial role in vaccination efforts.
— Curated by the World Pulse Now AI Editorial System